Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(19 sites)
United States
University of Arkansas Medical School, Little Rock, Arkansas University of California - Los Angeles, Los Angeles, California UCSF, San Francisco, California SCRI at HealthOne, Denver, Colorado Florida Cancer Specialists & Research Institute, Lake Mary, Florida AdventHealth Cancer Institute, Orlando, Florida Emory Winship Cancer Institute, Atlanta, Georgia Augusta University, Augusta, Georgia University of Kansas, Fairway, Kansas Dana Farber Cancer Institute, Boston, Massachusetts John Theurer Cancer Center at Hackensack UMC, Hackensack, New Jersey Sidney Kimmell Cancer Center - Jefferson Health, Philadelphia, Pennsylvania UPMC, Pittsburgh, Pennsylvania Sarah Cannon Research Institute (SCRI), Nashville, Tennessee NEXT Oncology, Austin, Texas UT Southwestern, Dallas, Texas Intermountain Health, Salt Lake City, Utah University of Virginia, Charlottesville, Virginia NEXT Virginia, Fairfax, Virginia